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Restenosis remains a significant clinical problem
more than 15 years after percutaneous angioplasty
was first developed to manage atherosclerotic occlu-
sions of arteries.1,2 The neointimal response of a
blood vessel to operative or other injury involves a
complex interplay of cells, cytokines, and growth
factors, a process that in many respects is similar to
healing responses in other tissues.3 In this process,
the smooth muscle cell (SMC) is central. SMCs are
numerically the predominant proliferative cell in the
injury-induced intimal lesion. They also produce the
extracellular matrix that provides up to 50% of the
volume of the neointima as healing progresses
beyond the cell proliferation stage.4 In the course of
neointimal formation, the SMC must undergo a
profound change in function from a nondividing,
contractile cell within the tunica media to a mobile
or dividing (or both) cell producing extracellular
proteins within the tunica intima.5 The phenotypi-
cally altered SMC differs from the cells of the media
in shape, expression of cytokines, histocompatibility
antigens, contractile and other protein types, and
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matrix protein synthesis.6 These differences in phe-
notype are distinguished by a decrease in the volume
fraction of myofilaments (Vvmyo) within the cyto-
plasm and an increase in other organelles. However,
although in a great deal of research the mechanism
or mechanisms responsible for this SMC response to
injury within blood vessels have been considered, lit-
tle attention has been paid to how the SMCs in the
normal mature artery wall are maintained in a quies-
cent phenotype with a high Vvmyo.
It often is assumed that SMCs remain quiescent
only through the absence of cytokines, and this is
reflected in the considerable research examining the
influence of cytokines on the SMC response to
injury. The possibility exists that there also are nat-
ural inhibitors of SMC proliferation present in the
normal artery, actively maintaining the SMCs in
their normal quiescent state. Injury not only pre-
sents numerous cytokines to the SMCs5 but also
removes from the same SMCs these natural
inhibitors that keep them in a quiescent, high
Vvmyo phenotype. Understanding how cells are
maintained in this phenotype is important because it
is only after a change in phenotype at the time of
injury that the SMC is able to respond to the multi-
ple mitogens and chemoattractant cytokines associ-
ated with injury.6
We have suggested7 that heparan sulfate proteo-
glycans (HSPGs) are the natural inhibitors of SMC
proliferation in the normal artery and that they main-
tain SMCs in the quiescent phenotype. The HSPGs
are a diverse family of proteoglycans within and
around all cells and thus are ideally placed to act in
phenotype maintenance.8 The possibility that HSPGs
may be antiproliferative molecules arises from the
known antiproliferative actions of the heparins,9
which are glycosaminoglycans (GAGs) closely related
to the heparan sulfate side chains of the HSPGs.
More recently, heparan sulfate GAG side chains from
both endothelial cell and cultured aortic SMC pro-
teoglycans10,11 have been shown to be similarly or
more potently inhibitory of SMC proliferation in
vitro compared with heparin. The present study
shows for the first time that natural heparan sulfates,
as whole proteoglycans isolated directly from the
arterial wall, also have inhibitory actions both in vitro
and in vivo and could prove to be effective therapeu-
tic tools to prevent restenosis in the clinical setting.
METHODS
Proteoglycan extraction and identification.
Proteoglycans were extracted from the aortas of
healthy 12- to 16-week-old rabbits by a two-step
digestion process. Aortae were homogenized in 6
Fig. 1. Typical elution profile for digested arterial tissue from DEAE-cellulose anion
exchange chromatography column. Fractions of 4 mL (monitored by absorbance at 280 nm)
were collected at a flow rate of 45 mL/hr with a 0.2 to 1.5 mol/L saline gradient.
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mol/L urea and 1 mol/L NaCl (10-mL solution/1
g of aorta) in the presence of protease inhibitors,
extracted for 24 hours, and then centrifuged at
10,000 rpm for 30 minutes. The supernatant was
retained, and the pellet was treated with 1% Triton
X-100, 0.2% deoxycholate, 2% sodium dodecyl sul-
fate, and 300 mmol/L Na phosphate buffer with
protease inhibitors for an additional 24 hours (mod-
ified from Galis et al.12). The homogenate was again
centrifuged at 10,000 rpm for 30 minutes, and the
supernatant was pooled with that from the urea
extraction. After overnight precipitation of the pro-
teins in absolute ethanol (3:1) at –20°C, the precip-
itate was resuspended in urea buffer (6 mol/L urea,
0.2 mol/L NaCl, 50 mmol/L Na acetate, pH 6.0)
in preparation for DEAE-cellulose anion exchange
chromatography at 4°C (DE52; Whatman,
Maidstone, England). After extensive washing (three
or four column volumes) with start buffer, elution of
proteoglycans was performed by applying a saline
gradient (0.2 to 1.5 mol/L). Then, 4.0-mL frac-
tions were collected at a flow rate of 45 mL/hr.
Fractions within individual peaks (monitored by
absorbance at 280 nm) eluted from the anion
exchange column were pooled and precipitated
overnight with ethanol at –20°C, centrifuged at
10,000 rpm for 30 minutes, and resuspended in
phosphate-buffered saline (PBS) for quantification
and identification.
The modified carbazole method13 was used to
quantify the amount of GAG within samples. Yield
was approximately 1 to 1.2 mg of GAG per gram
of artery extracted. The ratio of core protein (pro-
tein estimated by the method of Lowry et al.14) to
GAG was approximately 1:1.7. Identification of
proteoglycans was performed with sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (Protean
II system; BioRad, Hercules, Calif.) of samples
before and after heparitinase enzyme digestion.
Heparitinase (Seikagaku, Tokyo, Japan) was added
to the sample to a final concentration of 0.02
U/mL and incubated at 37°C for 6 hours. For
polyacrylamide gel electrophoresis analysis, 250-ng
samples of HSPG, before and after heparitinase
treatment, were applied to a 4% to 15% precast gel
(BioRad) with loading buffer under reducing con-
ditions. The gel was run for 4 hours at 65 mV and
then stained using a modification of the Alcian
blue-silver stain procedure.15
In vivo studies. A rabbit carotid arterial model
was used to study the effect of HSPGs on the devel-
opment of neointimal hyperplasia after arterial
injury. Animal care complied with the Principles of
Laboratory Care (formulated by the National
Society for Medical Research) and the Guide to the
Care and Use of Laboratory Animals (NIH
Publication No. 80-23, revised 1985). After the
induction of anesthesia with propofol (10 mg/kg),
25 half-lop rabbits (12 to 16 weeks old) were intu-
bated and maintained under anesthesia with
halothane. The right common carotid artery was
exposed operatively and de-endothelialized with a
2F Fogarty catheter to produce arterial injury along
its entire length from the aortic arch to the carotid
bifurcation.16 The distal 20 mm of common carotid
artery was dissected completely free from surround-
ing tissues, and 200 m L of a 25% F-127 pluronic gel
(BASF; Wyandotte) containing either HSPG (680
m g based on GAG content; 400 m g protein; group 1,
n = 9), Enoxaparin (2000 m g; group 2, n = 8), or gel
only (group 3, n = 8) was placed to coat the exposed
distal carotid arterial segment in a similar manner to
Fig. 2. The 4% to 15% polyacrylamide gel showing the
three bands of HSPGs (arrows) within the first peak eluted
from anion exchange chromatography. Samples of 250 ng
were added to each lane. Lane 1, untreated sample from
peak 1 (see Fig. 1). Lane 2, peak 1 after heparitinase action.
Molecular weights are indicated (right) (Alcian blue-silver
stain). The band at approximately 70 kDa (lane 2) has
bovine serum albumin used as stabilizer in the heparitinase
preparation used to degrade the heparan sulfate GAG.
JOURNAL OF VASCULAR SURGERY
Volume 28, Number 2 Bingley et al 311
the method of Simons et al.17 The pluronic gel was
formulated in PBS and maintained at 4°C. At this
temperature, it is a liquid and gels rapidly on the
artery after application via a syringe. After the oper-
ation, the rabbits were fed a standard rabbit chow.
At 14 days later, the rabbits were killed by an over-
dose of phenobarbitone (340 mg/kg), and the right
common carotid artery was removed for histological
analysis of neointimal formation. The distal 20-mm
and proximal 20-mm portions of the artery were
divided into 3- to 4-mm rings, fixed in glutaralde-
hyde, and embedded in paraffin. The middle portion
of artery was discarded. After paraffin embedding, a
minimum of six 5- m m sections from each area of
artery were stained with toluidine blue, and the ratio
of the intimal and medial cross-sectional areas
(IMR) was quantified using Mocha image-analysis
software (Jandel Scientific, San Rafael). The left
carotid artery was removed from some animals and
showed a very low IMR of approximately 0.01 as
expected. The IMR values for the treated distal ends
of the right carotid arteries formed the main set of
data. Statistical comparisons between groups were
made with the logarithms of the IMR of the distal
segments of artery by a one-way analysis of variance
(ANOVA) with a subsequent Dunnett’s multiple
comparison test for HSPG or Enoxaparin versus
control. P < .05 in one-tailed tests (ie, IMR less than
controls) was regarded as significant. To test
whether the proximal segments constituted an
appropriate control, we used a split-unit ANOVA
with nested replicates using the general linear model
in SAS (SAS Institute, Cary, N.C.). The overall P
value for the treatment (HSPG, Enoxaparin, or gel
only) · site (proximal or distal artery) interaction
was .092. P values for each treatment (distal vs prox-
imal artery sites) were .032, .404, and .319 for
HSPG, Enoxaparin, and gel only, respectively.
Gel release studies. To assess the time course
for HSPG release from 25% F-127 pluronic gel, 35S-
labeled HSPGs were synthesized by confluent
bovine endothelial cells exposed to 50 m Ci/mL 35S-
sulfate (25 Ci/mg sulfur; Amersham, Arlington
Heights, Ill.) per 90-mm dish for 7 days. HSPGs
then were extracted from the matrix laid down in a
method identical to that described above for extrac-
tion from whole aortae. The radiolabeled HSPGs
were mixed with a 25% w/v pluronic gel, and 0.5
mL of the gel was placed into the bottom of 7-mL
scintillation tubes. Next, 2.0 mL of PBS at 37°C was
carefully layered on top of the gel, and the tube was
sealed. At various time points, 2.0 mL was carefully
pipetted from the top of the tube without disturbing
the bottom layer. The counts remaining in all tubes
were measured with a beta counter (Beckman,
Fullerton) at the end of the experiment. The exper-
iments were performed in triplicate for each time
point. The percentage remaining in the lower layer
was calculated as a percentage of controls, which
consisted of 0.5 mL of labeled gel left for the dura-
tion of the experiment without PBS.
For in vivo release studies, the 35S-labeled
HSPGs then were incorporated into a 25% w/v
pluronic gel (250,000 dpm in 0.2 mL of pluronic
gel). In four rabbits, surgery was performed as
above, and 0.2 mL of gel containing 35S-labeled
HSPG was applied around the artery. Rabbits were
killed at 24, 48, and 96 hours and 7 days after gel
placement, at which times the carotid arteries were
collected and paraffin-embedded. Sections of
artery were cut, and the slides were dipped into an
emulsion of Kodak NTB2 Liquid Emulsion for
autoradiography and exposed for 14 days before
development.
In vitro studies. Cells from 9- to 12-week-old
rabbit aortae were collagenase-dispersed as previous-
ly described.18 Both primary aortic SMCs and SMCs
at passage 3 were plated at moderate cell density in
Medium 199 plus 5% fetal calf serum (10,000 cells
per well, 96-well plate) and allowed to adhere. After
Fig. 3. Intima-to-media ratios 14 days after de-endothe-
lialization in rabbit carotid arteries and periadventitial
treatment of the distal section of artery with 25% pluron-
ic gel containing saline (control) (n = 8), 2000 m g of
Enoxaparin (n = 8), or 680 m g of HSPG (n = 9). Values
are mean ± SEM. *Significantly different at P < .05.
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24 hours, proteoglycan samples in PBS (100· con-
centrates) were added to give final concentrations in
the medium of 1, 10, 50, and 100 m g/mL. On day
6 for primary cells and day 3 for passaged cells, 1
m Ci/mL (0.1 m Ci/well) 3H-thymidine (Amersham)
was added for 5 hours before cells were harvested for
counting in a beta counter. Eight individual wells
were used for each experimental group, with data
pooled from three independent experiments.
Comparisons between groups were performed with
one-way ANOVAs with Dunnett’s method for com-
parisons against controls.
The effects of HSPGs on SMC phenotype also
were studied in vitro. Primary rabbit aortic SMCs
were plated at moderate cell density in Medium 199
plus 5% fetal calf serum (4.5 · 105 cells/well in six-
well plates) and allowed to adhere for 24 hours.
Medium was exchanged to include either HSPGs at
34 m g/mL (based on GAG content; 20 m g/mL of
core protein), Enoxaparin at 100 m g/mL, or control
medium alone (three wells per group). At 5 days after
plating, cells were fixed in 2.5% glutaraldehyde and
embedded in Epon-araldyte for electron microscopy.
We cut 90-nm transmission electron microscopy sec-
tions from each block, which represented a single
well of cells (ie, three blocks per treatment group).
Photographs of cells (30 photographs per treatment
group) were taken by selecting the cell in the top
right of each grid square to obtain an unbiased sam-
ple for analysis. The percentage volume fraction of
myofilaments (%Vvmyo) was measured by point-
counting morphometry as previously described,18
expressed as mean ± SEM, and comparison between
groups was made by one-way ANOVA.
RESULTS
HSPG extraction and identification. The elu-
tion profile of aortic proteoglycans from DEAE-cel-
lulose anion exchange chromatography, monitored
by absorbance at 280 nm (Fig. 1), showed two dis-
tinct peaks eluted at 0.30 mol/L (peak I) and 0.5
mol/L (peak II). Previous work indicates that peak
I is mainly HSPG and peak 2 is mainly chondroitin
sulfate proteoglycans.11,19 Polyacrylamide gel elec-
Fig. 4. Representative light microscopic sections showing the effects of topical delivery on the
degree of neointimal formation in rabbit distal common carotid arteries at 14 days after de-
endothelialization. a, Control, gel only. b, Enoxaparin (2000 m g). c, HSPG (680 m g). L =
lumen; IEL = internal elastic lamina; M = media; N = neointima.
from the control distal ends). The neointimas in the
distal end of Enoxaparin-treated arteries or the gel-
only control group did not differ significantly from
the proximal ends of these arteries using this paired
analysis (P = .404 and .319, respectively), but the
ends did differ significantly in the HSPG group (P =
.032). All rabbits were included in both these analy-
ses, even those with a relatively low IMR in the prox-
imal section of their balloon catheter-injured artery.
Fig. 4 shows representative photomicrographs of
arteries from each group at 14 days after injury.
Release of HSPGs from 25% F-127 pluronic
gel. The time course was examined for release of
HSPG from 25% pluronic gel. Previous studies of
release from pluronic gels had shown that large mol-
ecules are slower to leave gels and that they do so in
vitro by gel dissolution rather than by diffusion.22
Using the in vitro system outlined in Methods,
HSPGs were found to be released from the gel in an
exponential manner with a half-life of approximately
30 hours (Fig. 5), although the distinct demarcation
between gel and overlying solution was no longer
visible after 8 hours. 35S-Labeled HSPGs also were
incorporated into pluronic gel applied to the adven-
titial surface of arteries in vivo. 35S-Labeling was
observed by autoradiography in the adventitial and
the outer medial layer of the rabbit carotid artery 24
hours after application and in the inner media by 48
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trophoresis of these peaks showed three major areas
of proteoglycan staining on the gel from peak I
ranging in molecular mass from 90 to greater than
400 kDa (Fig. 2). Proteoglycans do not run as sharp
bands on electrophoresis mainly due to the micro-
heterogeneity of the GAG side chains. Degradation
by bacterial heparitinase of peak I (Fig, 2, lane 2)
indicated that this peak was HSPG. A protein band
resolving at around 350 kDa after degradation of the
heparan sulfate side chains is indicative of a core pro-
tein of one of the large-molecular-weight HSPGs.
Other lower-molecular-weight core proteins also are
likely to be present in this heterogeneous mixture of
arterial HSPG but were not unequivocally identi-
fied. The heparan sulfate content in peak I was used
for measuring dose in subsequent in vitro and in
vivo studies. The protein content also was measured
and indicated a protein-to-GAG ratio of 1:1.7.
In vivo effects of HSPGs on neointimal hyper-
plasia formation after arterial injury. To study the
effects HSPGs may have on the response of arteries
to acute injury, rabbit common carotid artery was
injured by balloon de-endothelialization followed by
the application of HSPGs (group 1, 680 m g GAG
and 400 m g protein content) or Enoxaparin (group
2, 2000 m g GAG) within a 25% F-127 pluronic gel
vehicle (0.2 mL) to the periadventitial surface of the
20-mm distal segment. Control animals (group 3)
received pluronic gel only applied to that 20-mm dis-
tal segment of the balloon de-endothelialized com-
mon carotid artery. Two weeks after injury, arteries
were analyzed for neointimal formation. We exam-
ined the proximal area of each artery to determine
whether it could be used as an internal control to
take account of the between-rabbit variation in the
degree of intimal thickening caused by the balloon
catheter de-endothelialization.
The rabbits developed a neointima within 14 days
after injury (distal area in control mean ± SEM IMR,
0.215 ± 0.028, n = 8). The neointima that developed
in the arteries treated with HSPGs was significantly
smaller (mean IMR, 0.139 ± 0.016, n = 9; P = .029),
but the Enoxaparin-treated group was not signifi-
cantly different than the controls (Fig. 3). This 35%
decrease in neointimal thickening is striking given
that our model induces a relatively mild injury with
an IMR after 2 weeks of approximately 0.2, which is
considerably less than that in many similar studies
with an IMR of 1.0 or more.17,20,21 The data using
the proximal sections as internal controls for each
rabbit supported this result. The mean neointimal
thickening at the proximal ends of the arteries was
0.195 ± 0.017 (n = 25, not significantly different
Fig. 5. In vitro release of HSPG from 25% F-127 pluron-
ic gel showing the amount of 35S-labeled HSPG remain-
ing in a 25% F-127 pluronic gel at 37°C after removal of
overlying PBS at various time points. A line-of-best-fit
shows a half-life of approximately 30 hours.
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hours, but it was not detected at 4 and 7 days. Even
at the 24-hour time point, there was no visible gel
remaining in the periadventitial region.
In vitro effect of HSPGs and Enoxaparin on
smooth muscle cell phenotype and DNA synthesis.
The effect of arterial HSPGs on SMC phenotype in
vitro was striking (Fig. 6). When SMC enzyme dis-
persed from the artery wall were grown for 5 days in
primary culture in the presence of HSPGs (34
m g/mL GAG, 20 m g/mL protein content), there
was almost complete inhibition of the usual pheno-
type change seen in untreated SMC at 5 days in cul-
ture (Vvmyo, 52.1% ± 2.5% vs 35.9% ± 2.2%; n = 35;
P < .0001). Indeed, the SMCs showed a similar
Vvmyo as that of cells taken directly from the arter-
ial wall (54.1% ± 2.9%). In contrast, 100 m g/mL
Enoxaparin had little effect on the phenotype
change that occurs 5 days after dispersion in prima-
ry culture, showing a Vvmyo value indistinguishable
from that of control SMCs (38.9% ± 2.2%; P > .05
compared with controls). The morphological differ-
ences among HSPG-treated, Enoxaparin-treated,
and control SMCs are shown in Fig. 7.
The antiproliferative effects on rabbit aortic
SMCs of HSPGs extracted from normal arteries were
studied in vitro and compared with the antiprolifera-
tive effects of the low-molecular-weight heparin
Enoxaparin (and with the non-HSPGs isolated dur-
ing chromatography, predominantly chondroitin sul-
fate proteoglycans; peak 2). The HSPGs at concen-
trations as low as 0.1 m g/mL GAG (P < .0001)
inhibited thymidine incorporation by rabbit aortic
SMCs after 6 days in primary culture, with an ID50
of 0.40 m g/mL (Fig. 8, a). In contrast, Enoxaparin
was about 35-fold less potent than HSPG, with an
ID50 of 14 m g/mL. The chondroitin sulfate proteo-
glycans from rabbit arteries (peak 2) had no effect on
SMC thymidine incorporation at any concentration
(P > .5). In separate experiments, Enoxaparin
showed similar activity to unfractionated heparin
(Sigma Chemical, St. Louis, Mo.) and commercial
heparan sulfate of either low (Sigma) or high molec-
ular weight (Seikagaku) in inhibiting DNA synthesis
in SMC primary cultures (results not shown).
Both the HSPGs and Enoxaparin were less
markedly inhibitory on thymidine incorporation in
the passaged rabbit aortic SMCs without any serum
deprivation to induce quiescence. No inhibition was
observed below 50 m g/mL. Low-dose Enoxaparin
actually stimulated SMC growth compared with
controls, with 1 m g/mL Enoxaparin inducing a 65%
increase in 3H-thymidine incorporation (P < .001;
Fig. 8, b).
DISCUSSION
This study is the first to show that HSPGs
extracted from the arterial wall inhibit neointimal
formation in vivo and inhibit SMC phenotype
change and proliferation in vitro. This effect con-
trasts markedly with that of the related low-molecu-
lar-weight heparin (Enoxaparin), which had no effect
on SMC phenotype or neointima formation at three
times higher concentration than the HSPGs and
inhibited SMC proliferation at high concentration
only. In this study, we wanted to examine the activi-
ty of the natural HSPGs rather than degrade them to
the free heparan sulfate GAGs. The activity of the
HSPGs and Enoxaparin was tested on the compara-
ble per-microgram-of-GAG-chain basis, although as
side chains of GAG with the HSPGs or as free chains
with Enoxaparin because the GAG chain is known to
be the biologically active portion of the molecule.8
A number of studies using animal models9,20,23
have shown inhibition of neointimal formation by
heparin and by low-molecular-weight heparins,
including Enoxaparin,24 generally administered
intravenously or subcutaneously. Continuity of
treatment and the length of time heparin is present
were shown to be important factors,20 as well as the
Fig. 6. Mean volume fraction of myofilaments (±SEM) of
primary rabbit aortic SMCs cultured in Medium 199 plus
5% fetal calf serum in the presence of 34 m g/mL HSPG,
100 m g/mL Enoxaparin, or medium only (control) for 5
days. The proportion of cytoplasm filled with myofila-
ments (%Vvmyo), indicative of SMC phenotype, was cal-
culated by point-counting morphometry.
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dose. Release from ethylene-vinyl acetate copolymer
matrix pellets in the perivascular space has reduced
the size of neointimal thickening of the balloon-
injured rat carotid artery at doses of 7.6 mg of stan-
dard heparin and 19 mg of low-molecular-weight
nonanticoagulant heparin.21 More recently, lower
doses (3 to 5 mg of heparin23) or 700 m g of
heparin20 have been shown to be effective. Okada et
al.25 used 400 U of heparin (approximately 2.6 mg)
in a polyvinyl alcohol gel within a periadventitial cuff
and showed a reduced neointima. In the present
study, we chose a dose of 2 mg of the low-molecu-
lar-weight heparin Enoxaparin, which had shown
similar activity to heparin and was less likely to pro-
duce a wound hematoma at the site of application.
Based on our in vitro studies that indicated our
heparan sulfate preparation was significantly more
active, we chose a lower dose for the arterial heparan
sulfate preparation (680 m g GAG, 400 m g protein
content). Our rabbit carotid artery balloon catheter
injury model induces mild injury (IMR = 0.2 after 2
weeks), considerably less than in many similar stud-
ies with IMR of 1.0 or more.17,20,21 We used the
technique of Simons et al.17 for local delivery in a
periadventitial gel. Our in vitro and in vivo gel
release data suggest that release of HSPG occurs pri-
marily over the first 24 hours and is almost certainly
complete by 48 hours. It also is possible that the
HSPG delivered is being degraded during this time
even though we still observed its biological activity.
Characteristics and actions of heparin often are
attributed to heparan sulfates, yet there are several
important differences between heparins and HSPGs
that make such an analogy less certain. First, the two
Fig. 7. Representative electron micrographs of primary rabbit aortic SMCs cultured for 5 days
in Medium 199 plus 5% fetal calf serum with (a) medium only, (b) 100 m g/mL Enoxaparin,
and (c) 34 m g/mL HSPG. Myo = myofilament; E.R. = endoplasmic reticulum; M = mito-
chondria. Original magnification, 12,500· .
JOURNAL OF VASCULAR SURGERY
316 Bingley et al August 1998
differ in structure, with heparin more heavily N-
acetylated and sulfated.26 There are several families of
HSPGs that differ greatly in size, core protein, and
number and size of heparan sulfate side chains.8,27 In
addition, heparan sulfates exist as proteoglycans (ie,
GAG chains covalently bound to a core protein),28
whereas heparins are liberated from their core pro-
teins before release. The diverse family groups of
HSPGs, which are located in vastly different areas in
and around cells, are recognized to have diverse 
and separate functions, and heparan sulfate GAG
chains have a well-organized domain structure.29
Functionally different HSPGs are known to be pro-
duced by arterial SMCs.11 The heparins, for all their
well-demonstrated heterogeneity and multiple
actions, originate from only one location (mast
cell/basophils) and are likely to be produced for nar-
rower physiological purposes. Our arterial HSPG
preparation was highly active even though it con-
tained a mixture of different HSPGs, suggesting that
if (as expected) the activity is due to the specific func-
tion of a particular HSPG, it is active at much lower
concentrations than heparin, which can only mimic
its action. HSPGs are known to vary quantitatively
from adventitia to intima and to be in specific loca-
tions in the artery wall30 and are decreased in ather-
osclerotic lesions.31 Both perlecan,32 the large extra-
cellular matrix HSPG, and the syndecans,33 the
major family of cell membrane HSPGs, are known to
be modulated after arterial injury.
To undergo functional change from a contractile
to a migratory and proliferating cell, the SMC first
must change phenotype.6 Maintenance of a “con-
tractile” (high Vvmyo) phenotype is an indication
that the SMCs have not begun the changes they must
undergo in producing the neointimal lesion. The
potent effect of HSPGs on phenotype maintenance
in vitro, and consequent inhibition of DNA synthesis
of the primary cultured cells (especially compared
with Enoxaparin), supports the suggestion that this is
one of the roles for HSPG in situ in the normal
artery. Although the ID50 value for HSPG to inhibit
DNA synthesis of SMCs in primary culture was 0.4
m g/mL, 50% inhibition of thymidine incorporation
was not attained even at 100 m g/mL with passaged
cells. Although passaged cells not induced into qui-
escence by serum deprivation are reported to be con-
siderably less sensitive to heparin inhibiton,34 it
appears likely that, as for heparin, the effects on pro-
moting differentiation and inhibiting proliferation
are separate.35 Recent evidence that heparin has a
reduced effect on intimal SMCs compared with
medial SMCs in a repeat balloon injury rat aorta
model36 is consistent with this hypothesis.
If heparan sulfates are natural inhibitors of SMC
phenotype change and proliferation and their loss is
necessary for a response to injury, there must be a
mechanism for their removal after injury. The cells
associated with acute inflammation (platelets37, neu-
trophils,38 and macrophages39) are all known to
degrade HSPGs with either specific heparanases or
serine proteases. Macrophages, acting through a
Fig. 8. 3H-Thymidine incorporation by (A) rabbit aortic SMCs in Medium 199 plus 5% fetal
calf serum at day 6 in primary culture and (B) third-passage rabbit aortic SMCs in Medium
199 plus 5% fetal calf serum at day 3 after treatment with HSPGs (d), Enoxaparin (n ), or
chondroitin sulfate proteoglycans (n) at varying doses, shown as a percentage of control.
Values are mean ± SEM of three separate measurements (eight replicates per experiment).
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lysosomal heparitinase, modulate the phenotype of
contractile SMCs in vitro.7 Moreover, the SMCs are
capable of altering their own HSPG expression.40
Enoxaparin and, to a lesser extent, HSPG were
growth stimulatory for passaged SMCs at low con-
centrations. It is known that SMCs with a low Vvmyo
value have an 11-fold increase in fibroblast growth
factor receptors compared with SMCs with a high
Vvmyo value41 and that heparan sulfate is a necessary
cofactor in the mitogenic action of fibroblast growth
factor through its surface receptor.42 At low concen-
trations, binding of growth factors and promotion of
growth factor cell signaling may dominate any
growth-inhibitory effects.43 The finding that heparin
derivatives have opposing effects on SMC prolifera-
tion at different concentrations adds a layer of com-
plexity to their potential use as therapeutic agents and
may in part explain poor clinical experience with
heparins in restenosis to date. The experimental20 and
clinical data44,45 suggest that when heparin is given in
widely spaced (greater than 12 hours) doses, the
degree of neointimal formation worsens, an effect
that is reversed when it is given continuously. Local
delivery to the artery at the time of surgery may be
appropriate, although methods other than the exper-
imental periadventitial application used here would be
necessary clinically (eg, via a delivery catheter).
The lack of success to date in preventing resteno-
sis through pharmacological manipulation may, in a
large part, be due to a general lack of understanding
of the mechanisms of cell growth and phenotype
modulation, including the factors that maintain a
cell in its normal state. The results of the current
study raise the possibility that within normal blood
vessels, HSPGs are involved in maintaining the
“contractile” high Vvmyo state of SMCs (and thus
their ability to contract) and that the addition of
HSPG, stimulation of its synthesis, or inhibition of
its degradation may provide an effective method for
limiting neointimal formation after arterial injury.
We acknowledge the advice of Ms Joan Hendrikz,
Statistical Advisor to the Biological Sciences Group,
University of Queensland.
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